Clinical Trial Update: BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

The Phase 2 BEZ235 (dactolisib) trial in HER2-negative, HR-positive metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BEZ235 (dactolisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Breast Cancer | Phase 2 | Status: WITHDRAWN